Interferon Gamma 1-b

DRUG3 trials

Sponsors

National Eye Institute (NEI), Assistance Publique - Hôpitaux de Paris, University Hospital, Limoges

Conditions

Adult Patients Admitted to Intensive Care With Initial Severity (SOFA of the First 24 Hours Post-admission ≥ 6Adult Under Mechanical Ventilation, and Presenting an mHLA-DR Less Than 8,000AB/CPost-aggressive ImmunosuppressionSustained ImmunosuppressionUveitis

Phase 1

The Treatment of Uveitic Cystoid Macular Edema With Topical Interferon Gamma

CompletedNCT00943982

National Eye Institute (NEI)Uveitis

Start: 2009-07-17End: 2010-06-24Updated: 2017-07-02

Phase 2

Effect of Interferon Gamma as a Treatment for Post-aggressive Immunosuppression in Intensive Care Units, a Randomized Bayesian Double-blind Controlled Trial Versus Placebo

RecruitingNCT06694740

Assistance Publique - Hôpitaux de ParisAdult Patients Admitted to Intensive Care With Initial Severity (SOFA of the First 24 Hours Post-admission ≥ 6, Adult Under Mechanical Ventilation, and Presenting an mHLA-DR Less Than 8,000AB/C, Post-aggressive Immunosuppression

Start: 2026-02-24End: 2029-05-01Target: 170Updated: 2026-07-06

Phase 3

Prevention of Secondary Infections by Interferon Gamma in ICU-acquired Sustained Immune-suppression

RecruitingNCT06774235

University Hospital, LimogesSustained Immunosuppression

Start: 2025-07-09End: 2028-10-09Target: 326Updated: 2025-11-20

Related Papers

Prevention of secondary infections by interferon-gamma in ICU-acquired sustained immune suppression in France: study protocol of the PLATINIUM randomised trial.

2026-01-27